Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献

英文中文

[18F]FDG PET/TC en la sospecha de linfoma primario del SNC: evaluación del compromiso sistémico y guía para biopsia [18F]FDG PET/TC在怀疑中枢神经系统原发性淋巴瘤中的应用：全身参与评估和活检指南

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-04-17 DOI: 10.1016/j.remn.2025.500140

P. Dauden-Onate , C. Gamila Wakfie-Corieh , R.M. Couto-Caro , M.L. Suarez-Solis , C. Benavente-Cuesta , M.N. Cabrera-Martín

引用次数: 0

18F-FDG PET-TC en la hidatidosis multifocal 18F-FDG PET-TC在多焦点包虫药中的作用

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-06-11 DOI: 10.1016/j.remn.2025.500176

G. Molina-Mendoza, M.P. Talavera Rubio, F. López-Bermejo García, J. Gatón Ramírez, V.M. Poblete García

引用次数: 0

PET/TC con 18F-colina en el estudio del hiperparatiroidismo primario: evaluación de la técnica, análisis visual y semicuantitativo y correlación con otras técnicas de imagen 在原发性甲状旁腺增生研究中使用18F-胆碱的PET/TC：技术评估、视觉和半定量分析以及与其他成像技术的相关性

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-08-18 DOI: 10.1016/j.remn.2025.500129

E. Campaña Díaz , F. Gómez-Caminero López , J.M. Álvarez Pérez , C. Montes Fuentes , S. Rama Alonso , J.Á. Badell Martínez , P. García-Talavera San Miguel

Objective

To assess the usefulness of performing a dual-time-point protocol in the acquisition of ¹⁸F-Choline (¹⁸F-FCH) PET/CT in the pre-surgical localization of PHPT, and to demonstrate the impact of this imaging technique on the management and outcome-based surgical decision making, compared to other imaging techniques. To evaluate the diagnostic performance of the test to discriminate between pathological parathyroid gland and cervical lymph node, as well as to establish its correlation with other imaging techniques (scintigraphy, ultrasound, CT and MRI).

Patients and methods

We included 39 patients who underwent surgery for PHPT, in whom dual-time-point 18F-FCH PET/CT was performed. Metabolic index of parathyroid (P-SUVmax; P-SUVpeak), lymph node (N-SUVpeak), thyroid (T-SUVpeak) and mediastinum (M-SUVpeak) uptake were analyzed visually and semiquantitatively in both images. PET/CT results were correlated with ^99mTc-MIBI scintigraphy, ultrasound, MRI and CT.

Results

In 36 patients (92%), PET/CT was positive, localizing 38 pathological glands. The sensitivity (S) of PET/TC was 97% and positive predictive value (PPV) 94%. In the visual analysis, dual-time-point protocol was necessary in 61% of the cases. Correlation between PET/TC with MRI was 80%, with 4D-CT 50%, and with the other techniques < 50%. P-SUVmax shows correlation with adenoma weight and size, and with presurgical PTH. The best cutoff point for SUVpeak to differentiate parathyroid vs. lymph node was 2.6 in early images (S = 70%; specificity = 75%; P=.007) and 0.86 for SUVpeak/T-SUVpeak index (S = 73%; specificity = 69%; P=.001).

Conclusion

18F-FCH PET/CT is an excellent preoperative localization technique in patients with PHPT with negative, doubtful or inconclusive imaging techniques, being of vital importance in guiding minimally invasive surgery. The dual-time-point protocol was necessary in more than half of the cases (61%). The SUVpeak cut-off points to discriminate between parathyroid gland and lymph nodes were statistically significant.

目的评估采用双时间点方案获取18f -胆碱（18F-FCH） PET/CT在PHPT术前定位中的有效性，并与其他成像技术相比，展示该成像技术对治疗和基于结果的手术决策的影响。评价该检查对病理性甲状旁腺和颈淋巴结的鉴别诊断价值，并与其他影像学技术（闪烁成像、超声、CT、MRI）建立相关性。患者和方法我们纳入了39例接受PHPT手术的患者，其中进行了双时间点18F-FCH PET/CT检查。对两幅图像的甲状旁腺代谢指数（P-SUVmax; P-SUVpeak）、淋巴结代谢指数（N-SUVpeak）、甲状腺代谢指数（T-SUVpeak）和纵隔代谢指数（M-SUVpeak）摄取进行目视和半定量分析。PET/CT结果与99mTc-MIBI显像、超声、MRI和CT结果相关。结果PET/CT阳性36例（92%），病灶腺体38个。PET/TC敏感性(S)为97%，阳性预测值（PPV）为94%。在目视分析中，61%的病例需要双时间点方案。PET/TC与MRI的相关性为80%，与4D-CT的相关性为50%，与其他技术的相关性为50%。P-SUVmax与腺瘤重量、大小及术前PTH相关。早期SUVpeak鉴别甲状旁腺与淋巴结的最佳截断点为2.6 (S = 70%，特异性= 75%，P= 0.007)， SUVpeak/T-SUVpeak指数的最佳截断点为0.86 （S = 73%，特异性= 69%，P= 0.001）。结论18f - fch PET/CT对于影像学阴性、可疑或不确定的PHPT患者是一种很好的术前定位技术，对指导微创手术具有重要意义。超过一半的病例（61%）需要双时间点方案。区分甲状旁腺和淋巴结的SUVpeak截止点具有统计学意义。

{"title":"PET/TC con 18F-colina en el estudio del hiperparatiroidismo primario: evaluación de la técnica, análisis visual y semicuantitativo y correlación con otras técnicas de imagen","authors":"E. Campaña Díaz , F. Gómez-Caminero López , J.M. Álvarez Pérez , C. Montes Fuentes , S. Rama Alonso , J.Á. Badell Martínez , P. García-Talavera San Miguel","doi":"10.1016/j.remn.2025.500129","DOIUrl":"10.1016/j.remn.2025.500129","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the usefulness of performing a dual-time-point protocol in the acquisition of <sup>18</sup>F-Choline (<sup>18</sup>F-FCH) PET/CT in the pre-surgical localization of PHPT, and to demonstrate the impact of this imaging technique on the management and outcome-based surgical decision making, compared to other imaging techniques. To evaluate the diagnostic performance of the test to discriminate between pathological parathyroid gland and cervical lymph node, as well as to establish its correlation with other imaging techniques (scintigraphy, ultrasound, CT and MRI).</div></div><div><h3>Patients and methods</h3><div>We included 39 patients who underwent surgery for PHPT, in whom dual-time-point 18F-FCH PET/CT was performed. Metabolic index of parathyroid (P-SUVmax; P-SUVpeak), lymph node (N-SUVpeak), thyroid (T-SUVpeak) and mediastinum (M-SUVpeak) uptake were analyzed visually and semiquantitatively in both images. PET/CT results were correlated with <sup>99m</sup>Tc-MIBI scintigraphy, ultrasound, MRI and CT.</div></div><div><h3>Results</h3><div>In 36 patients (92%), PET/CT was positive, localizing 38 pathological glands. The sensitivity (S) of PET/TC was 97% and positive predictive value (PPV) 94%. In the visual analysis, dual-time-point protocol was necessary in 61% of the cases. Correlation between PET/TC with MRI was 80%, with 4D-CT 50%, and with the other techniques <50%. P-SUVmax shows correlation with adenoma weight and size, and with presurgical PTH. The best cutoff point for SUVpeak to differentiate parathyroid vs. lymph node was 2.6 in early images (S=70%; specificity=75%; <em>P</em>=.007) and 0.86 for SUVpeak/T-SUVpeak index (S=73%; specificity=69%; <em>P</em>=.001).</div></div><div><h3>Conclusion</h3><div>18F-FCH PET/CT is an excellent preoperative localization technique in patients with PHPT with negative, doubtful or inconclusive imaging techniques, being of vital importance in guiding minimally invasive surgery. The dual-time-point protocol was necessary in more than half of the cases (61%). The SUVpeak cut-off points to discriminate between parathyroid gland and lymph nodes were statistically significant.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500129"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patrón característico en la PET/TC con [18F]FDG en la encefalitis antirreceptor NMDA NMDA抗受体性脑炎中[18F]FDG的PET/TC特征模式

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-01-18 DOI: 10.1016/j.remn.2024.500084

D.A. López-Mora , L. Lozano Murgas , M. Hervas Pujol , A.A. Rodríguez Revuelto

引用次数: 0

Detección incidental de carcinoma tiroideo y adenoma paratiroideo con 18F-Fluorocolina PET/CT Detección偶发性腺状癌伴腺状旁腺瘤，18F-Fluorocolina PET/CT

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-04-07 DOI: 10.1016/j.remn.2025.500136

G. Cuesta Domingo , C. Rodríguez Rey , A. Ortega Candil , P. Nespral Torres , S. Ochagavía Cámara , M.N. Cabrera Martín

引用次数: 0

Aortitis micótica causada por BCG intravesical y cáncer de pulmón concomitante identificado mediante 18F-FDG PET/TC 经18F-FDG PET/ CT鉴定的静脉注射卡介苗引起的真菌性主动脉炎和并发肺癌

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-07-11 DOI: 10.1016/j.remn.2025.500130

K. Oksuzoglu, N. Zumbul

引用次数: 0

Revolucionando el tratamiento del cáncer de próstata: la terapia dirigida al antígeno prostático específico en el enfoque moderno terapéutico 彻底改变前列腺癌的治疗：现代治疗方法中的前列腺特异性抗原治疗

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-05-13 DOI: 10.1016/j.remn.2025.500162

A. Ricaurte Fajardo , V. Marulanda Corzo , S. Ruder , D.R. Cardoza-Ochoa , C.E. Granados , D. Yadav , D. Lopez , M. Fatima , S. Dutruel , E. O’Dwyer , J.R. Osborne , S.T. Tagawa , S. Huicochea Castellanos

Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy has reshaped the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), offering new therapeutic possibilities beyond conventional approaches. Among the most promising strategies is lutetium-177 PSMA-617, which has shown significant benefits in overall survival and durable PSA responses, as demonstrated in several clinical trials.

At the same time, the development of novel radionuclides such as actinium-225 has opened the door to more potent treatments capable of overcoming prior resistance, particularly in patients previously exposed to beta emitters. The use of PSMA PET imaging and the identification of predictive biomarkers have helped refine patient selection, contributing to a more personalized approach. Comparative studies with agents like cabazitaxel have further supported the safety and effectiveness of this strategy.

This article provides a critical overview of clinical advances in PSMA-targeted radionuclide therapy, examines emerging combination treatments, reviews the development of alpha-emitting agents, and highlights the role of personalized dosimetry in clinical practice, underlining the growing importance of this therapeutic modality across different stages of prostate cancer.

前列腺特异性膜抗原（PSMA）靶向放射性核素治疗重塑了转移性去势抵抗性前列腺癌（mCRPC）的治疗前景，提供了超越传统方法的新治疗可能性。其中最有希望的策略是luteium -177 PSMA-617，在几项临床试验中显示出在总生存期和持久PSA反应方面的显着益处。与此同时，新型放射性核素（如锕-225）的开发为更有效的治疗打开了大门，能够克服先前的耐药性，特别是对先前暴露于β排放物的患者。PSMA PET成像的使用和预测性生物标志物的识别有助于改进患者选择，有助于更个性化的方法。与卡巴他赛等药物的比较研究进一步支持了该策略的安全性和有效性。本文概述了psma靶向放射性核素治疗的临床进展，研究了新兴的联合治疗方法，回顾了α释放剂的发展，并强调了个性化剂量测定在临床实践中的作用，强调了这种治疗方式在前列腺癌不同阶段的重要性。

{"title":"Revolucionando el tratamiento del cáncer de próstata: la terapia dirigida al antígeno prostático específico en el enfoque moderno terapéutico","authors":"A. Ricaurte Fajardo , V. Marulanda Corzo , S. Ruder , D.R. Cardoza-Ochoa , C.E. Granados , D. Yadav , D. Lopez , M. Fatima , S. Dutruel , E. O’Dwyer , J.R. Osborne , S.T. Tagawa , S. Huicochea Castellanos","doi":"10.1016/j.remn.2025.500162","DOIUrl":"10.1016/j.remn.2025.500162","url":null,"abstract":"<div><div>Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy has reshaped the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), offering new therapeutic possibilities beyond conventional approaches. Among the most promising strategies is lutetium-177 PSMA-617, which has shown significant benefits in overall survival and durable PSA responses, as demonstrated in several clinical trials.</div><div>At the same time, the development of novel radionuclides such as actinium-225 has opened the door to more potent treatments capable of overcoming prior resistance, particularly in patients previously exposed to beta emitters. The use of PSMA PET imaging and the identification of predictive biomarkers have helped refine patient selection, contributing to a more personalized approach. Comparative studies with agents like cabazitaxel have further supported the safety and effectiveness of this strategy.</div><div>This article provides a critical overview of clinical advances in PSMA-targeted radionuclide therapy, examines emerging combination treatments, reviews the development of alpha-emitting agents, and highlights the role of personalized dosimetry in clinical practice, underlining the growing importance of this therapeutic modality across different stages of prostate cancer.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500162"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factores natriuréticos y biomarcadores de inflamación como predictores de supervivencia en la terapia con [177Lu]Lu-DOTA-TATE de los tumores neuroendocrinos 钠尿因子和炎症生物标志物作为神经内分泌肿瘤[177Lu]Lu-DOTA-TATE治疗生存率的预测指标

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-04-07 DOI: 10.1016/j.remn.2025.500138

A. Piñeiro Donis , L. Menéndez-Muros , J.L. Villa-Palacios , E. Triviño-Ibáñez , M.A. Muros-Fuentes

Objective

To analyze the prognostic value of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and other biomarkers of inflammation in patients with neuroendocrine tumors (NETs) treated with [¹⁷⁷Lu]Lu-DOTA-TATE (Lutathera®). The prognostic value of histological characteristics of the tumor was also analyzed.

Patients and methods

Prospective study of a cohort of patients with advanced and metastatic NETs treated with [¹⁷⁷Lu]Lu-DOTA-TATE. Before the administration of doses, NT-proBNP, hemoglobin, hematocrit, C-reactive protein, leukocytes, lymphocytes, neutrophils, neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) have been determined. Overall survival (OS) and progression free survival (PFS) were calculated, using the Kaplan-Meier method, and curves were compared with a log-rank test. To determine the predictor variables of OS, a Cox regression model was fitted.

Results

48 NET patients treated with [¹⁷⁷Lu]Lu-DOTA-TATE. Median OS was 96 months and PFS was 29 months. Factors associated with lower OS were: NTproBNP values > 300 pg/mL (HR: 10.5; P = .005) in the subgroup of patients with grades 2-3, in addition to inflammatory indices NLR > 2 (HR: 3.87; P = .049) and PLR > 300 (HR: 11.88; P = .01) and higher tumor grade (HR: 6.45; P = .011). PLR > 300 (HR: 5.506; P = .003) was also associated with lower PFS. In contrast, higher levels of lymphocytes (HR: 0.21; P = .002), hemoglobin (HR: 0.65; P = .041) and hematocrit (HR: 0.862; P = .031) were associated with higher OS, without significant changes in PFS.

Conclusion

In patients with NETs treated with [¹⁷⁷Lu]Lu-DOTA-TATE, the determination of natriuretic factors (NT-ProBNP) and other inflammatory biomarkers may be useful as predictors of survival and prognostic factors.

目的分析脑利钠肽n端原激素（NT-proBNP）及其他炎症生物标志物在应用[177Lu]Lu-DOTA-TATE （Lutathera®）治疗神经内分泌肿瘤（NETs）患者中的预后价值。并分析肿瘤的组织学特征对预后的影响。患者和方法一组接受[177Lu]Lu-DOTA-TATE治疗的晚期和转移性NETs患者的前瞻性研究。给药前，测定NT-proBNP、血红蛋白、红细胞压积、c反应蛋白、白细胞、淋巴细胞、中性粒细胞、中性粒细胞/淋巴细胞比值（NLR）和血小板/淋巴细胞比值（PLR）。采用Kaplan-Meier法计算总生存期（OS）和无进展生存期（PFS），并用log-rank检验比较曲线。为确定OS的预测变量，拟合Cox回归模型。结果48例NET患者采用[177Lu]Lu-DOTA-TATE治疗。中位OS为96个月，PFS为29个月。与较低OS相关的因素有：2-3级患者亚组NTproBNP值>； 300 pg/mL (HR: 10.5; P = 0.005)，炎症指数NLR >； 2 （HR: 3.87; P = 0.049）和PLR >； 300 （HR: 11.88; P = 0.01）和较高的肿瘤分级（HR: 6.45; P = 0.011）。PLR > 300 （HR: 5.506; P = 0.003）也与较低的PFS相关。相比之下，淋巴细胞（HR: 0.21, P = 0.002）、血红蛋白（HR: 0.65, P = 0.041）和红细胞压积（HR: 0.862, P = 0.031）水平升高与OS升高相关，PFS无显著变化。结论在接受[177Lu]Lu-DOTA-TATE治疗的NETs患者中，利钠因子（NT-ProBNP）和其他炎症生物标志物的测定可能有助于预测生存和预后因素。

{"title":"Factores natriuréticos y biomarcadores de inflamación como predictores de supervivencia en la terapia con [177Lu]Lu-DOTA-TATE de los tumores neuroendocrinos","authors":"A. Piñeiro Donis , L. Menéndez-Muros , J.L. Villa-Palacios , E. Triviño-Ibáñez , M.A. Muros-Fuentes","doi":"10.1016/j.remn.2025.500138","DOIUrl":"10.1016/j.remn.2025.500138","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the prognostic value of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and other biomarkers of inflammation in patients with neuroendocrine tumors (NETs) treated with [<sup>177</sup>Lu]Lu-DOTA-TATE (Lutathera®). The prognostic value of histological characteristics of the tumor was also analyzed.</div></div><div><h3>Patients and methods</h3><div>Prospective study of a cohort of patients with advanced and metastatic NETs treated with [<sup>177</sup>Lu]Lu-DOTA-TATE. Before the administration of doses, NT-proBNP, hemoglobin, hematocrit, C-reactive protein, leukocytes, lymphocytes, neutrophils, neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) have been determined. Overall survival (OS) and progression free survival (PFS) were calculated, using the Kaplan-Meier method, and curves were compared with a log-rank test. To determine the predictor variables of OS, a Cox regression model was fitted.</div></div><div><h3>Results</h3><div>48 NET patients treated with [<sup>177</sup>Lu]Lu-DOTA-TATE. Median OS was 96months and PFS was 29months. Factors associated with lower OS were: NTproBNP values>300pg/mL (HR: 10.5; <em>P</em>     =.049) and PLR>300 (HR: 11.88; <em>P</em>  =.011). PLR>300 (HR: 5.506; <em>P</em>  =.002), hemoglobin (HR: 0.65; <em>P</em>  =.031) were associated with higher OS, without significant changes in PFS.</div></div><div><h3>Conclusion</h3><div>In patients with NETs treated with [<sup>177</sup>Lu]Lu-DOTA-TATE, the determination of natriuretic factors (NT-ProBNP) and other inflammatory biomarkers may be useful as predictors of survival and prognostic factors.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 5","pages":"Article 500138"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enfermedad de Erdheim Chester: diagnóstico y valoración de respuesta con PET/TC [18F]FDG Erdheim Chester病：用PET/ CT [18F]FDG进行诊断和反应评估

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-06-10 DOI: 10.1016/j.remn.2025.500179

S. López Puche , J.G. Villanueva Curto , P. García-Talavera San Miguel , J.A. Badell Martínez , S. Rama Alonso , M.P. Tamayo Alonso

引用次数: 0

Encuesta nacional sobre la imagen nuclear en patología ósea infecciosa: resultados y recomendaciones diagnósticas del Grupo de Trabajo de Patología Musculoesquelética (GT-PME) 全国感染性骨病核成像调查：肌肉骨骼病理工作组的结果和诊断建议

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2025-09-01 Epub Date: 2025-05-23 DOI: 10.1016/j.remn.2025.500165

E. Noriega-Álvarez , A. Moreno-Ballesteros , M. Velasco Nuño , J.M. Cordero García , J.J. Rosales Castillo , U.V. Schmülling , E. López Rodríguez , A. Rigabert Sánchez-Junco , B. Rodríguez Alfonso

The continued increase in demand for diagnosis and monitoring of infectious bone diseases, along with the introduction of new equipment, radiopharmaceuticals, and techniques for this purpose, has made it necessary to dynamically update the existing protocols and recommendations. Therefore, the MSP-WG conducted a survey for spanish hospitals to complete and develop recommendations in the form of algorithms, in an attempt to combine existing scientific evidence with the reality of national clinical practice.

对传染性骨病诊断和监测的需求不断增加，同时为此目的引进了新设备、放射性药物和技术，因此有必要对现有的规程和建议进行动态更新。因此，MSP-WG对西班牙医院进行了一项调查，以完成和制定算法形式的建议，试图将现有的科学证据与国家临床实践的现实相结合。

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Revista Espanola De Medicina Nuclear E Imagen Molecular

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀